Keywords
Hematuria
Sodium-Glucose Transporter 2 Inhibitors
Glomerulonephritis
IGA
How to Cite
Abstract
Background: IgA nephropathy is a prevalent glomerulopathy that can lead to chronic kidney disease and renal failure. Traditional treatment focuses on nephroprotection and proteinuria control.
Purpose: To evaluate the effect of sodium-glucose cotransporter type 2 (iSGLT-2) inhibitors in reducing proteinuria in patients with IgA nephropathy without diabetes.
Case presentation: We describe three cases of patients with primary IgA nephropathy without diabetes, who presented persistent proteinuria despite conventional treatment with ACEI/ARA II. After starting Dapagliflozin, a significant reduction in proteinuria was observed, reaching subnephrotic levels within months.
Discussion and conclusion: The results suggest a potential benefit of iSGLT-2 in modulating proteinuria in patients with IgA nephropathy, possibly mediated by effects on intraglomerular pressure and inflammatory response. The use of iSGLT-2 in non-diabetic IgA nephropathy patients may represent a promising strategy for nephroprotection. Further studies are required to confirm these findings and determine their long-term impact.
References
McGrogan A, Franssen CFM, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414-30. https://doi.org/10.1093/ndt/gfq665
Scionti K, Molyneux K, Selvaskandan H, Barratt J, Cheung CK. New insights into the pathogenesis and treatment strategies in IgA nephropathy. Glomerular Dis. 2022;2(1):15-29. https://doi.org/10.1159/000519973
Yamamoto R, Nagasawa Y, Shoji T, Iwatani H, Hamano T, Kawada N, et al. Cigarette smoking and progression of IgA nephropathy. Am J Kidney Dis. 2010;56(2):313-24. https://doi.org/10.1053/j.ajkd.2010.02.351
Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677-86. https://doi.org/10.2215/CJN.07420716
Tesa? V. SGLT2 inhibitors in non-diabetic kidney disease. Adv Clin Exp Med. 2022;31(2):105-7. https://doi.org/10.17219/acem/145734
Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95(2):281-95. https://doi.org/10.1016/j.kint.2018.11.008
McQuarrie EP, Gillis KA, Mark PB. Seven suggestions for successful SGLT2i use in glomerular disease - a standalone CKD therapy? Curr Opin Nephrol Hypertens. 2022;31(3):272-7. https://doi.org/10.1097/MNH.0000000000000786
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-46. https://doi.org/10.1056/NEJMoa2024816
The EMPA-Kidney Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-27. https://doi.org/10.1056/NEJMoa2204233
Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (Diamond): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020;8(7):582-93. https://doi.org/10.1016/S2213-8587(20)30162-5
Wheeler DC, Toto RD, Stefánsson BV, Jongs N, Chertow GM, Greene T, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1):215-24. https://doi.org/10.1016/j.kint.2021.03.033
Dong Y, Shi S, Liu L, Zhou X, Lv J, Zhang H. Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy. Front Med. 2023;10:1242241. https://doi.org/10.3389/fmed.2023.1242241
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.